Three-dimensional radiobiologic dosimetry: Application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry

Journal of Nuclear Medicine

Volumn 48, Issue 6, 2007, Pages 1008-1016

  Prideaux, Andrew R ^a   Song, Hong ^a   Hobbs, Robert F ^a   He, Bin ^a   Frey, Eric C ^a   Ladenson, Paul W ^a,b   Wahl, Richard L ^a   Sgouros, George ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

3D ID; Dosimetry; Patient specific dosimetry; Radiobiology; Treatment planning

Indexed keywords

RADIOACTIVE IODINE; RADIOISOTOPE;

ARTICLE; CALCULATION; COMPUTER ASSISTED TOMOGRAPHY; DOSIMETRY; DRUG ACCUMULATION; DRUG CLEARANCE; HISTOGRAM; HUMAN; IMAGE ANALYSIS; LUNG PARENCHYMA; MONTE CARLO METHOD; PHANTOM; PREDICTION; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIOBIOLOGY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THREE DIMENSIONAL IMAGING; THYROID CANCER; TREATMENT PLANNING; TREATMENT RESPONSE;

HUMANS; IMAGING, THREE-DIMENSIONAL; IODINE RADIOISOTOPES; MODELS, BIOLOGICAL; MONTE CARLO METHOD; NEOPLASMS; PHANTOMS, IMAGING; RADIATION DOSAGE; RADIOMETRY; RADIOPHARMACEUTICALS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34250345988     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.106.038000     Document Type: Article

References (40)

1. Sgouros G. Dosimetry of internal emitters. J Nucl Med. 2005;46(suppl):18S-27S.
2. Stabin M. Nuclear medicine dosimetry. Phys Med Biol. 2006;51:R187-R202.
3. Chiavassa S, Aubineau L, Bitar A, et al. Validation of a personalized dosimetric evaluation tool (Oedipe) for targeted radiotherapy based on the Monte Carlo MCNPX code. Phys Med Biol. 2006;51:601-616.
4. Flux GD, Webb S, Ott RJ, Chittenden SJ, Thomas R. Three-dimensional dosimetry for intralesional radionuclide therapy using mathematical modeling and multimodality imaging. J Nucl Med. 1997;38:1059-1066.
5. Furhang EE, Chui CS, Kolbert KS, Larson SM, Sgouros G. Implementation of a Monle Carlo dosimelry method for patient-specific internal emitter therapy. Med Phys. 1997;24:1163-1172.
6. Kolbert KS, Sgouros G, Scott AM, et al. Implementation and evaluation of patient-specific three-dimensional internal dosimetry. J Nucl Med. 1997;38:301-308.
7. Sgouros G, Barest G, Thekkumtbala J, et al. Treatment planning for internal radionuclide therapy: three-dimensional dosimetry for nonuniformly distributed radionuclides. J Nucl Med. 1990;31:1884-1891.
8. Tagesson M, Ljungberg M, Strand SEA. Monte-Carlo program converting activity distributions to absorbed dose distributions in a radionuclide treatment planning system. Acta Oncol. 1996;35:367-372.
9. Sgouros G, Kolbert KS. The three-dimensional internal dosimetry software package, 3D-ID. In: Zaidi H, Sgouros G, eds. Therapeutic Applications of Monte Carlo Calculations in Nuclear Medicine. Philadelphia, PA: Institute of Physics; 2002;249-261.
10. Flynn AA, Pedley RB, Green AJ, et al. The nonuniformity of antibody distribution in the kidney and its influence on dosimetry. Radiat Res. 2003;159:182-189.
11. Humm JL, Cobb LM. Nonuniformity of tumor dose in radioimmunotherapy. J Nucl Med. 1990;31:75-83.
12. Muthuswamy MS, Roberson PL, Ten Haken RK, Buchsbaum DJ. A quantitative study of radionuclide characteristics for radioiinmunotherapy from 3D reconstructions using serial autoradiography. Int J Radiat Oncol Biol Phys. 1996;35:165-172.
13. O'Donoghue JA. Implications of nonuniform tumor doses for radioimmunotherapy. J Nucl Med. 1999;40:1337-1341.
14. O'Donoghue JA, Sgouros G, Divgi CR, Humm JL. Single-dose versus fractionated radioimmunothcrapy: model comparisons for uniform tumor dosimetry. J Nucl Med. 2000;41:538-547.
15. Kolbert KS, Sgouros G, Scott AM, et al. Dose-volume histogram representation of patient dose distribution in 3-dimensional internal dosimetry [abstract]. J Nucl Med. l994;35(suppl):123P-124P.
16. Hall EJ. Radiation dose-rate: a factor of importance in radiobiology and radiotherapy. Br J Radiol. 1972;45:81-97.
17. Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol. 1989;62:679-694.
18. Barendsen GW. Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys. 1982;8:1981-1997.
19. Behr TM, Memtsoudis S, Sharkey RM, et al. Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: influence of radiation dose and dose rate on toxicity and anti-tumor efficacy. Int J Cancer. 1998;77:787-795.
20. Flynn AA, Pedley RB, Green AJ, et al. Effectiveness of radiolabeled antibodies for radio-immunolherapy in a colorectal xenograft model: a comparative study using the linear-quadratic formulation. Int J Radial Biol. 2001;77:507-517.
21. Rao DV, Howell RW. Time-dose-fractionation in radioimmunotherapy: implications for selecting radionuclides. J Nucl Med. 1993;34:1801-1810.
22. 124I PET and 3-dimensional-internaI dosimetry (3D-ID) software. J Nucl Med. 2004;45:1366-1372.
23. 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med. 1999;40:1935-1946.
24. 131I-anti-B1 antibody: assessment of tumor dose-response. J Nucl Med. 2003;44:260-268
25. Furhang EE, Chui CS, Sgouros G. A Monte Carlo approach to patient-specific dosimetry. Med Phys. 1996;23:1523-1529.
26. Dale R, Carabe-Fernandez A. The radiobiology of conventional radiotherapy and its application to radionuclide therapy. Cancer Biother Radiopharm. 2005;20:47-51.
27. Millar WT. Application of the linear-quadratic model with incomplete repair to radionuclide directed therapy. Br J Radiol. 1991;64:242-251.
28. Van Dyk J, Mah K, Keane TJ. Radiation-induced lung damage: dose-time-fractionation considerations. Radiother Oncol. 1989;14:55-69.
29. Gaussen A, Legal JD, Beron-Gaillard N, et al. Radiosensitivity of human normal and tumoral thyroid cells using fluorescence in situ hybridization and clonogenic survival assay. Int J Radiat Biol. 1999;44:683-691.
30. Challeton C, Branea F, Schlumberger M, et al. Characterization and radiosensitivity at high and low dose rate of four cell lines derived from human thyroid tumors. Int J Radiat Oncol Biol Phys. 1997;37:163-169.
31. Bodey RK, Flux GD, Evans PM. Combining dosimetry for targeted radionuclide and external beam therapies using the biologically effective dose. Cancer Biother Radiopharm. 2003;18:89-97.
32. Song H, He B, Prideaux A, et al. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases. J Nucl Med. 2006;47:1985-1994.
33. Frey EC, Gilland KL, Tsui BM. Application of task-based measures of image quality to optimization and evaluation of three-dimensional reconstruction-based compensation methods in myocardial perfusion SPECT. IEEE Trans Med Imaging. 2002;21:1040-1050.
34. De Jong M, Valkema R, Jamar F, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med. 2002;32:133-140.
35. Goldenberg DM, Sharkey RM, Paganelli G, Barbel J, Chatal JF. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol. 2006;24:823-834.
36. Zhu H, Jain RK, Baxter LT. Tumor pretargeting for radioimmunodetection and radioimmunotherapy. J Nucl Med. 1998;39:65-76.
37. Boerman OC, Oyen WJ, Corstens FH. Between the Scylla and Charybdis of peptide radionuclide therapy: hitting the tumor and saving the kidney. Eur J Nucl Med. 2001;28:1447-1449.
38. 166Ho-DOTMP. Cancer Biother Radiopharm. 2003;18:225-230.
39. Bodey RK, Evans PM, Flux GD. Application of the linear-quadratic model to combined modality radiotherapy, Int J Radiat Oncol Biol Phys. 2004;59:228-241.
40. Rajendran JG, Schwartz DL, O'Sullivan J. et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res. 2006;12:5435-5441.